Publication | Closed Access

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

Daily Oral CediranibNational Cancer InstituteOncologyMedicinePharmacokinetic StudyBronchial NeoplasmAnti-cancer AgentCancer TreatmentLung CancerPharmacologyRadiation OncologyTumor Microenvironment